Drug Profile
ISPI 55
Alternative Names: ISP I 55Latest Information Update: 05 Jun 2001
Price :
$50
*
At a glance
- Originator Mitsubishi Pharma Corporation; Taito
- Class Small molecules
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders; Transplant rejection
Most Recent Events
- 05 Jun 2001 Discontinued-Preclinical for Autoimmune disorders in Japan (Unknown route)
- 05 Jun 2001 Discontinued-Preclinical for Transplant rejection in Japan (Unknown route)
- 06 Aug 1998 No-Development-Reported for Autoimmune disorders in Japan (Unknown route)